GEFISAB works as an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, blocking signals that stimulate tumour cell growth and division. It is most effective in patients with known EGFR-activating mutations.
Recommended for:
Non-small cell lung cancer (NSCLC), metastatic or locally advanced
Patients with confirmed EGFR mutations
When chemotherapy is not suitable or as first-line targeted therapy
Disease progression after prior cancer treatment
Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation-positive status.
Typically prescribed as one tablet (250mg) daily, with or without food. Duration of treatment depends on clinical response and tolerability as assessed by the physician.
Hypersensitivity to gefitinib or excipients
Severe hepatic impairment
Co-administration with strong CYP3A4 inducers
Pregnancy and breastfeeding unless clearly indicated
Diarrhoea
Skin rash, itching
Dry skin
Elevated liver enzymes
Interstitial lung disease (rare)
Eye discomfort or dryness
